<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Aust Prescr</journal-id><journal-id journal-id-type="iso-abbrev">Aust Prescr</journal-id><journal-id journal-id-type="publisher-id">AP</journal-id><journal-title-group><journal-title>Australian Prescriber</journal-title></journal-title-group><issn pub-type="ppub">0312-8008</issn><issn pub-type="epub">1839-3942</issn><publisher><publisher-name>NPS MedicineWise</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31937994</article-id><article-id pub-id-type="pmc">6954874</article-id><article-id pub-id-type="publisher-id">austprescr-42-211</article-id><article-id pub-id-type="doi">10.18773/austprescr.2019.075</article-id><article-categories><subj-group subj-group-type="heading"><subject>New Drugs</subject></subj-group></article-categories><title-group><article-title>Crisaborole for atopic dermatitis</article-title></title-group><pub-date pub-type="epub"><day>02</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2019</year></pub-date><volume>42</volume><issue>6</issue><fpage>211</fpage><lpage>211</lpage><permissions><copyright-statement>(c) NPS MedicineWise 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>NPS MedicineWise</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license></permissions></article-meta></front><body><p>Approved indication: atopic dermatitis</p><p>Staquis (Pfizer)</p><p>tubes containing 2.5 mg and 60 mg 2% ointment</p><p>When mild to moderate atopic dermatitis does not respond to moisturisers and emollients, low-dose corticosteroids are usually prescribed. Crisaborole 2% ointment is a new treatment for this condition and is approved for patients aged two years and over. It is a phosphodiesterase type 4 inhibitor and, although its mechanism of action is not clear, inhibiting the phosphodiesterase type 4 enzyme is known to suppress the secretion of pro-inflammatory cytokines such as tumour necrosis factor (TNF) alpha.</p><p>A thin layer of ointment should be applied to affected skin twice a day. After administration, 25% of the dose is absorbed. Crisaborole is then rapidly metabolised to inactive metabolites which are excreted by the kidneys. Drug interactions with cytochrome P450 enzymes are not expected. Concurrent use with other topical treatments for atopic dermatitis has not been evaluated.</p><p>Crisaborole has been investigated in two identical placebo-controlled studies of 1522 participants.<xref rid="r1" ref-type="bibr">1</xref> Most of them were children. They were evaluated using the Investigator&#x02019;s Static Global Assessment score (severity scale of 1&#x02013;4). At baseline, 38.5% of patients had mild disease (score of 2) and 61.5% had moderate disease (score of 3). Crisaborole ointment or vehicle alone was applied twice a day for 28 days. The primary end point of the trials was the proportion of patients who had clear (score of 0) or almost clear (score of 1) skin and at least a 2-point improvement in their score from baseline. At the end of the study period, significantly more of the patients who applied active treatment compared to placebo had successfully responded (31&#x02013;33% vs 18&#x02013;25% of patients) (see <xref rid="t1" ref-type="table">Table</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table</label><caption><title>Efficacy of twice-daily crisaborole 2% ointment for mild&#x02013;moderate atopic dermatitis</title></caption><table frame="hsides" rules="groups"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><thead><tr><th valign="top" align="left" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">-</th><th colspan="3" valign="top" align="left" scope="colgroup" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1">Proportion of patients who successfully responded after 28 days of treatment*</th></tr><tr><th valign="top" align="left" scope="col" style="border-bottom: solid 0.50pt" rowspan="1" colspan="1">-</th><th valign="top" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Crisaborole (1016 patients)</th><th valign="top" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Placebo vehicle (506 patients)</th><th valign="top" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td valign="top" align="left" style="border-top: solid 0.50pt; background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">Trial 1</td><td valign="top" align="left" style="border-top: solid 0.50pt; background-color:rgb(242,242,242)" rowspan="1" colspan="1">32.8%</td><td valign="top" align="left" style="border-top: solid 0.50pt; background-color:rgb(242,242,242)" rowspan="1" colspan="1">25.4%</td><td valign="top" align="left" style="border-top: solid 0.50pt; background-color:rgb(242,242,242)" rowspan="1" colspan="1">0.038</td></tr><tr><td valign="top" align="left" style="border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Trial 2</td><td valign="top" align="left" style="border-bottom: solid 0.50pt" rowspan="1" colspan="1">31.4%</td><td valign="top" align="left" style="border-bottom: solid 0.50pt" rowspan="1" colspan="1">18%</td><td valign="top" align="left" style="border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>* The primary efficacy end point was the proportion of patients who had clear (score of 0) or almost clear (score of 1) skin evaluated using the Investigator&#x02019;s Static Global Assessment score (severity scale of 1&#x02013;4), and at least a 2-point improvement in their score from baseline.</p><p>Source: reference <xref rid="r1" ref-type="bibr">1</xref></p></table-wrap-foot></table-wrap><p>Crisaborole ointment was well tolerated in the trials. The most common treatment-related adverse effect was burning or stinging at the application site. This affected 4.4% of those in the crisaborole group and 1.2% in the control group.<xref rid="r1" ref-type="bibr">1</xref> Contact urticaria has been reported with this ointment (&#x0003c;1% of patients). A 48-week, single-arm extension trial of 517 participants assessed the long-term safety of 28-day treatment courses. The most common treatment-related adverse events included worsening or flare of atopic dermatitis (3.1%), and pain (2.3%) and infection (1.2%) at the application site.<xref rid="r2" ref-type="bibr">2</xref></p><p>Topical crisaborole seemed to be effective as a short-term treatment for mild to moderate atopic dermatitis. However, there have been no comparative trials with topical corticosteroids so far. Longer-term efficacy is yet to be established.</p><p><inline-graphic xlink:href="austprescr-42-211-g1.jpg"/><ext-link ext-link-type="uri" xlink:href="https://www.nps.org.au/australian-prescriber/articles/new-drugs-transparency-1">manufacturer provided additional useful information</ext-link></p></body><back><fn-group><fn id="fn1"><p>The Transparency Score is explained in <ext-link ext-link-type="uri" xlink:href="https://www.nps.org.au/australian-prescriber/articles/new-drugs-transparency-1">New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27</ext-link>. At the time the comment was prepared, information about this drug was available on the websites of the <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/">Food and Drug Administration</ext-link> in the USA and the <ext-link ext-link-type="uri" xlink:href="http://www.tga.gov.au/industry/pm-auspar.htm">Therapeutic Goods Administration</ext-link>.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Tom</surname><given-names>WL</given-names></name><name><surname>Lebwohl</surname><given-names>MG</given-names></name><name><surname>Blumenthal</surname><given-names>RL</given-names></name><name><surname>Boguniewicz</surname><given-names>M</given-names></name><name><surname>Call</surname><given-names>RS</given-names></name><etal/></person-group>
<article-title>Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults</article-title>. <source>J Am Acad Dermatol</source>
<year>2016</year>;<volume>75</volume>:<fpage>494</fpage>-<lpage>503.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2016.05.046</pub-id><pub-id pub-id-type="pmid">27417017</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichenfield</surname><given-names>LF</given-names></name><name><surname>Call</surname><given-names>RS</given-names></name><name><surname>Forsha</surname><given-names>DW</given-names></name><name><surname>Fowler</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Hebert</surname><given-names>AA</given-names></name><name><surname>Spellman</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis</article-title>. <source>J Am Acad Dermatol</source>
<year>2017</year>;<volume>77</volume>:<fpage>641</fpage>-<lpage>649.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2017.06.010</pub-id><pub-id pub-id-type="pmid">28823881</pub-id></mixed-citation></ref></ref-list></back></article>